Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial

被引：0

作者：

Jun Guo

Jie Jin

Mototsugu Oya

Hirotsugu Uemura

Shunji Takahashi

Katsunori Tatsugami

Sun Young Rha

Jae-Lyun Lee

Jinsoo Chung

Ho Yeong Lim

Hsi Chin Wu

Yen Hwa Chang

Arun Azad

Ian D. Davis

Marlene J. Carrasco-Alfonso

Bhupinder Nanua

Jackie Han

Qasim Ahmad

Robert Motzer

机构：

[1] Peking University Cancer Hospital and Institute,Department Urology and Melanoma

[2] Peking University First Hospital,Department of Urology

[3] Keio University School of Medicine,Department of Urology

[4] Kindai University Faculty of Medicine,Department of Urology

[5] Cancer Institute Hospital,Department of Medical Oncology

[6] Japanese Foundation for Cancer Research,Department of Urology, Graduate School of Medical Sciences

[7] Kyushu University,Department of Oncology and Internal Medicine, Asan Medical Center

[8] Yonsei Cancer Center,Department of Urology

[9] Yonsei University College of Medicine,Division of Hematology

[10] University of Ulsan College of Medicine,Oncology

[11] Center for Prostate Cancer,Department of Urology

[12] National Cancer Center,Division of Urology, Department of Surgery

[13] Samsung Medical Center,Department of Medicine

[14] Sungkyunkwan University,Department of Medicine

[15] China Medical University Hospital,undefined

[16] Taipei Veterans General Hospital,undefined

[17] Monash University,undefined

[18] Monash University,undefined

[19] Eastern Health Clinical School,undefined

[20] Novartis Pharmaceuticals Corporation,undefined

[21] Novartis Pharmaceuticals Corporation,undefined

[22] Genitourinary Oncology Service,undefined

[23] Memorial Sloan-Kettering Cancer Center,undefined

来源：

Journal of Hematology & Oncology | / 11卷

关键词：

Renal cell carcinoma; Pazopanib; Sunitinib;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[31] Cost-Effectiveness Analysis of Sunitinib versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore
Pruis, Sil-ling
Aziz, Mohamed Ismail Abdul
Pearce, Fiona
Tan, Min Han
Wu, David Bin-Chia
Ng, Kwong
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2019, 35 (02) : 126 - 133
[32] Pazopanib as a second-line treatment for non-cytokine-treated metastatic renal cell carcinoma: a meta-analysis of the effect of treatment
Victor C. Kok
Jung-Tsung Kuo
BMC Urology, 16
[33] Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis
Campbell, Matthew T.
Bilen, Mehmet A.
Shah, Amishi Y.
Lemke, Emily
Jonasch, E.
Venkatesan, A. M.
Altinmakas, E.
Duran, C.
Msaouel, Pavlos
Tannir, N. M.
EUROPEAN JOURNAL OF CANCER, 2018, 104 : 188 - 194
[34] Sunitinib for Patients with Metastatic Non-clear Cell Renal Cell Carcinoma: A Multicenter Retrospective Turkish Oncology Group Trial
Yildiz, Ibrahim
Ekenel, Meltem
Akman, Tulay
Kocar, Muharrem
Uysal, Mukremin
Kanitez, Metin
Varol, Umut
Bayoglu, Ibrahim Vedat
Tural, Deniz
Kaplan, Mehmet Ali
Avci, Nilufer
Surmeli, Zeki
Dede, Isa
Ulas, Arife
Yazici, Ozan
Basaran, Mert
ANTICANCER RESEARCH, 2014, 34 (08) : 4329 - 4334
[35] First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials
Takyar, Shweta
Diaz, Jose
Sehgal, Manu
Sapunar, Francisco
Pandha, Hardev
ANTI-CANCER DRUGS, 2016, 27 (05) : 383 - 397
[36] Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial
Zhou, Ai-Ping
Bai, Yuxian
Song, Yan
Luo, Hong
Ren, Xiu-Bao
Wang, Xiuwen
Shi, Benkang
Fu, Cheng
Cheng, Ying
Liu, Jiyan
Qin, Shukui
Li, Jun
Li, Hanzhong
Bai, Xianzhong
Ye, Dingwei
Wang, Jinwan
Ma, Jianhui
ONCOLOGIST, 2019, 24 (08) : E702 - E708
[37] Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study
Grunwald, Viktor
Powles, Thomas
Kopyltsov, Evgeny
Kozlov, Vadim
Alonso-Gordoa, Teresa
Eto, Masatoshi
Hutson, Thomas
Motzer, Robert
Winquist, Eric
Maroto, Pablo
Keam, Bhumsuk
Procopio, Giuseppe
Wong, Shirley
Melichar, Bohuslav
Rolland, Frederic
Oya, Mototsugu
Rodriguez-Lopez, Karla
Saito, Kenichi
McKenzie, Jodi
Porta, Camillo
EUROPEAN UROLOGY ONCOLOGY, 2023, 6 (04): : 437 - 446
[38] Survival by depth of response and efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma: analysis of the phase 3 randomized CLEAR study
Gruenwald, V.
Powles, T.
Kopyltsov, E.
Kozlov, V.
Alonso-Gordoa, T.
Eto, M.
Hutson, T.
Motzer, R.
Winquist, E.
Maroto, P.
Keam, B.
Procopio, G.
Wong, S.
Melichar, B.
Rolland, F.
Oya, M.
Rodriguez-Lopez, K.
Saito, K.
McKenzie, J.
Porta, C.
ONKOUROLOGIYA, 2023, 19 (04): : 32 - 43
[39] Pazopanib as Second-Line Treatment After Sunitinib or Bevacizumab in Patients With Advanced Renal Cell Carcinoma: A Sarah Cannon Oncology Research Consortium Phase II Trial
Hainsworth, John D.
Rubin, Mark S.
Arrowsmith, Edward R.
Khatcheressian, James
Crane, Edward J.
Franco, Luis A.
CLINICAL GENITOURINARY CANCER, 2013, 11 (03) : 270 - 275
[40] Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma
Barrios, Carlos H.
Hernandez-Barajas, David
Brown, Michael P.
Lee, Se-Hoon
Fein, Luis
Liu, Jin-Hwang
Hariharan, Subramanian
Martell, Bridget A.
Yuan, Jinyu
Bello, Akintunde
Wang, Zhixiao
Mundayat, Rajiv
Rha, Sun-Young
CANCER, 2012, 118 (05) : 1252 - 1259

← 1 2 3 4 5 →